Back to results

Completed

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

NCT05913440

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Arkhangelsk, Russia

+39 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2023-05-30
Enrollment: 1,669 participants
Sponsor: AstraZeneca

Locations (40)

Research SiteArkhangelsk, Russia
Research SiteBarnaul, Russia
Research SiteBelgorod, Russia
Research SiteChelyabinsk, Russia
Research SiteChita, Russia
Research SiteGrozny, Russia
Research SiteIrkutsk, Russia
Research SiteIstra, Russia
Research SiteIzhevsk, Russia
Research SiteKaluga, Russia
Research SiteKemerovo, Russia
Research SiteKhanty-Mansiysk, Russia
Research SiteKirov, Russia
Research SiteKostroma, Russia
Research SiteKrasnodar, Russia
Research SiteKrasnoyarsk, Russia
Research SiteMaykop, Russia
Research SiteMoscow, Russia
Research SiteNal'chik, Russia
Research SiteNizhny Novgorod, Russia
Research SiteNovosibirsk, Russia
Research SiteOmsk, Russia
Research SiteOrenburg, Russia
Research SitePerm, Russia
Research SitePyatigorsk, Russia
Research SiteRyazan, Russia
Research SiteSaint Petersburg, Russia
Research SiteSaransk, Russia
Research SiteSevedorvinsk, Russia
Research SiteSmolensk, Russia
Research SiteSochi, Russia
Research SiteSurgut, Russia
Research SiteTomsk, Russia
Research SiteTver', Russia
Research SiteUfa, Russia
Research SiteUlan-Ude, Russia
Research SiteVladivostok, Russia
Research SiteVolgograd, Russia
Research SiteYaroslavl, Russia
Research SiteYuzhno-Sakhalinsk, Russia

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia — TrialFind